Expression of elongation factor-2 kinase contributes to anoikis resistance and invasion of human glioma cells

Acta Pharmacol Sin. 2011 Mar;32(3):361-7. doi: 10.1038/aps.2010.213. Epub 2011 Jan 31.

Abstract

Aim: To determine whether elongation factor-2 kinase (eEF-2 kinase) contributes to the malignant phenotype of glioblastoma multiforme by promoting the migration and invasion of glioma cells. The mechanism involved was also explored.

Methods: Human glioma cell lines T98G and LN-229 were used. The expression of eEF-2 kinase was silenced using siRNA, and the invasive potential of tumor cells was assessed using a wound-healing assay and a Matrigel invasion assay. Apoptosis was determined using propidium iodide (PI) staining and Western blot analysis of cleaved caspase-3.

Results: Silencing the expression of eEF-2 kinase by siRNA significantly suppressed both the migration and invasion of human glioma cells. Silencing eEF-2 kinase expression also sensitized glioma cells to anoikis, thereby decreasing tumor cell viability in the absence of attachment. Treatment of tumor cells with the caspase inhibitor z-VAD-fmk down-regulated Bim accumulation and abolished glioma cell sensitivity to anoikis.

Conclusion: The results suggest that the expression of eEF-2 kinase contributes to migration and invasion of human glioma cells by protecting them from anoikis. eEF-2 kinase expression may serve as a prognostic marker and a novel target for cancer therapy.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Anoikis*
  • Cell Line, Tumor
  • Elongation Factor 2 Kinase / genetics
  • Elongation Factor 2 Kinase / metabolism*
  • Glioblastoma / drug therapy
  • Glioblastoma / metabolism
  • Glioblastoma / pathology*
  • Glioma / drug therapy
  • Glioma / metabolism
  • Glioma / pathology*
  • Humans
  • Molecular Targeted Therapy
  • Neoplasm Invasiveness
  • RNA Interference

Substances

  • Elongation Factor 2 Kinase